Zenas Bio rises as Wedbush launches with Outperform on lead asset
Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.
pharmaphorum6d
Positive new phase 3 MRI data from UPLIZNA trial for NMOSD
Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...
Amgen outlook revised to positive by Fitch, ratings affirmed
Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...
Healio4d
‘Landmark’ B-cell depletion data offer hope to patients with IgG4-related disease
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Clinical Trials Arena on MSN6d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
pharmaphorum4d
US immunology biotech Zenas BioPharma files $100m IPO
It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...
Pharm Exec5d
Phase III Trial Shows Novartis’ Gene Therapy Significantly Improves Spinal Muscular Atrophy Outcomes
Results from the STEER and STRENGTH studies showed that OAV101 IT led to a 2.39-point improvement in motor function in patients with spinal muscular atrophy. Results from the Phase III STEER and Phase ...